Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 175,587 shares of the medical research company's stock after selling 6,167 shares during the quarter. Victory Capital Management Inc.'s holdings in Thermo Fisher Scientific were worth $108,613,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Signature Resources Capital Management LLC boosted its holdings in Thermo Fisher Scientific by 318.2% during the 2nd quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company's stock worth $25,000 after acquiring an additional 35 shares during the last quarter. New Millennium Group LLC purchased a new position in Thermo Fisher Scientific in the second quarter worth $29,000. Stephens Consulting LLC increased its position in shares of Thermo Fisher Scientific by 116.0% during the 2nd quarter. Stephens Consulting LLC now owns 54 shares of the medical research company's stock valued at $30,000 after purchasing an additional 29 shares during the last quarter. Headlands Technologies LLC purchased a new position in shares of Thermo Fisher Scientific in the 1st quarter worth about $32,000. Finally, Bank & Trust Co bought a new position in Thermo Fisher Scientific during the second quarter valued at about $33,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

TMO traded up $1.78 on Wednesday, reaching $542.53. 489,385 shares of the stock were exchanged, compared to its average volume of 1,458,339. Thermo Fisher Scientific Inc. has a fifty-two week low of $455.22 and a fifty-two week high of $627.88. The company's 50-day moving average price is $591.27 and its 200 day moving average price is $583.32. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. The firm has a market capitalization of $207.52 billion, a PE ratio of 33.90, a PEG ratio of 3.57 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating analysts' consensus estimates of $5.25 by $0.03. The company had revenue of $10.60 billion during the quarter, compared to analysts' expectations of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The firm's revenue for the quarter was up .2% on a year-over-year basis. During the same quarter in the previous year, the company earned $5.69 earnings per share. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. The ex-dividend date is Friday, December 13th. Thermo Fisher Scientific's payout ratio is 9.78%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 9,000 shares of Thermo Fisher Scientific stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $552.86, for a total transaction of $4,975,740.00. Following the transaction, the chief executive officer now directly owns 14,608 shares of the company's stock, valued at $8,076,178.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the transaction, the executive vice president now directly owns 16,663 shares in the company, valued at approximately $9,333,946.08. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 9,000 shares of the firm's stock in a transaction on Friday, November 8th. The stock was sold at an average price of $552.86, for a total value of $4,975,740.00. Following the sale, the chief executive officer now owns 14,608 shares in the company, valued at $8,076,178.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 37,150 shares of company stock valued at $20,651,865. Corporate insiders own 0.34% of the company's stock.

Analysts Set New Price Targets

TMO has been the subject of a number of research reports. Bank of America increased their target price on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a "buy" rating in a research report on Monday, September 16th. JPMorgan Chase & Co. boosted their target price on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an "overweight" rating in a research note on Friday, September 20th. Bernstein Bank lifted their price objective on Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a "market perform" rating in a report on Tuesday, October 22nd. Stifel Nicolaus cut their target price on Thermo Fisher Scientific from $680.00 to $665.00 and set a "buy" rating for the company in a research note on Thursday, October 24th. Finally, Evercore ISI cut their target price on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an "outperform" rating for the company in a research report on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and an average target price of $649.33.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.